We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Volatile Anesthetics for Hepatic Protection

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00516711
First Posted: August 15, 2007
Last Update Posted: September 15, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Zurich
  Purpose
This study aims to evaluate the attenuation of ischemic-reperfusion injury in the liver after sevoflurane preconditioning. In the presence of sevoflurane, an attenuation of liver injury is hypothesized (diminished increase of liver enzymes, reduced production of inflammatory mediators).

Condition Intervention
Reperfusion Injury Drug: Sevoflurane

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT)

Study Start Date: March 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:
Organ protection; preconditioning; volatile anesthetics; ischemia reperfusion
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Older than 18 years of age
  • Patients undergoing liver resection (benign or malignant tumors)

Exclusion Criteria:

  • Laparoscopic liver resection coagulopathy (platelets < 50,000/ml, Quick < 50%)
  • Liver cirrhosis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00516711


Locations
Switzerland
University Hospital of Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00516711     History of Changes
Other Study ID Numbers: StV 5-2006
First Submitted: August 14, 2007
First Posted: August 15, 2007
Last Update Posted: September 15, 2010
Last Verified: August 2007

Keywords provided by University of Zurich:
Surgery with Pringle maneuver needed for liver resection

Additional relevant MeSH terms:
Reperfusion Injury
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Pathologic Processes
Anesthetics
Sevoflurane
Central Nervous System Depressants
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Anesthetics, General